Clinical trials: Stroke, Embolic
Transcatheter Aortic Valve Replacement (TAVR), Cerebral Vascular Accident (CVA)/Stroke
Evaluation of the Safety and Effectiveness of CHORDS® Cerebral Protection System During TAVR: DUET Trial
This is a prospective, multi-center, randomized controlled study. The goal of the study is to assess the safety and effectiveness of the Resonova® CHORDS® Cerebral Protection System in capturing and removing embolic debris during…
- Trial name
- NCT07648693
- Testing
- CHORDS® Cerebral Protection System, Sentinel Cerebral Protection System
- Where
- 15 sites in China
- Volunteers
- 240 people
- Sponsor
- Resonova (Shanghai) Medtech Limited
Nonvalvular Atrial Fibrillation
Prevention of Stroke and Systemic Embolic Events in Patients With Atrial Fibrillation
The main purpose of this study is to provide dose-guiding information by assessing the safety and tolerability of 4 different dosing regimens of an extended-release (ER) formulation of AZD0837 compared with well-controlled…
- Trial name
- NCT00684307
- Testing
- AZD0837, Vitamin-K antagonist at INR 2-3
- Volunteers
- 1,084 people
- Sponsor
- AstraZeneca
Embolic Stroke, Postoperative Cognitive Dysfunction
Perfusion Pressure Cerebral Infarction Trial (PPCI)
STUDY HYPOTHESIS In cardiac surgery the volume of perioperative cerebral infarctions can be reduced by increasing mean arterial pressure (MAP) during the cardiopulmonary bypass procedure.
- Trial name
- PPCI (NCT02185885)
- Testing
- Increased bloodpressure during CPB.
- Where
- Denmark
- Volunteers
- 197 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Stroke, Secondary Prevention
Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)
This trial will enroll approximately 6,000 patients with recent embolic stroke of unknown source (ESUS). Patients will be randomized to dabigatran or acetylsalicyclic acid (ASA) (1:1 ratio) and have visits every three months.
- Trial name
- NCT02239120
- Testing
- optional ASA as comedication, ASA 100 mg
- Where
- 569 sites in United States, Argentina and 40 more
- Volunteers
- 5,390 people
- Sponsor
- Boehringer Ingelheim
Atrial Fibrillation, Stroke
Advanced Cardiac Imaging To Predict Embolic Stroke On Brain MRI: A Pilot Study
Demonstrating the pathophysiological link between Left Atrial (LA) and Left Atrial Appendage (LAA) pathology and embolic strokes in non-Atrial Fibrillation (AF) individuals represents a major advance in stroke prevention…
- Conditions
- Atrial Fibrillation, Stroke, Stroke, Cardiovascular, Vascular Cognitive Impairment
- Trial name
- NCT04769310
- Testing
- Cardiac and Brain MRI
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Tulane University
Stroke, Prevention
Rivaroxaban Plus ASA in Embolic Stroke of Undetermined Source(AREST-ESUS)
Approximately 17% of all patients with stroke are classified as having ESUS, which is associated with a considerable rate of stroke recurrence 4-5 % per year.
- Trial name
- AREST-ESUS (NCT04273516)
- Testing
- Rivaroxaban 2.5 Mg Oral Tablet
- Where
- Iran
- Volunteers
- 42 people
- Sponsor
- Mazandaran University of Medical Sciences
Ischemic Stroke, Atrial Fibrillation
Lixiana Acute Stroke Evaluation Registry
Study Design: Lixiana Acute Stroke Evaluation Registry (LASER) is a randomized controlled trial with an associated registry. Patients with previously known or newly diagnosed atrial fibrillation (AF) and acute ischemic stroke…
- Conditions
- Ischemic Stroke, Atrial Fibrillation, Hemorrhagic Transformation Stroke
- Trial name
- LASER (NCT03494530)
- Testing
- Edoxaban 60 MG, Edoxaban 30 mg
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- University of Alberta
Embolic Stroke of Undetermined Source
AI-Based Prediction of Atrial Fibrillation in ESUS Patients With ICM
This study investigates patients with Embolic Stroke of Undetermined Source (ESUS) who have received an Implantable Cardiac Monitor (ICM).
- Trial name
- SMART-ESUS (NCT07347691)
- Where
- 5 sites in South Korea
- Volunteers
- 92 people
- Sponsor
- Inha University Hospital
Delirium, Ischemic Stroke
CTSN Embolic Protection Trial
This is a prospective, multi-center, randomized effectiveness trial of the CardioGard Embolic Protection Cannula in high-risk valve surgery patients.
- Conditions
- Delirium, Ischemic Stroke, Acute Kidney Injury, Heart Valve Disease
- Trial name
- EMPRO (NCT06027788)
- Testing
- CardioGard Embolic Protection Cannula, Standard Aortic Cannula
- Where
- 24 sites in United States, Canada
- Volunteers
- 842 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Cerebral Embolization During TAVI Using Balloon-expandable vs. Self-expandable Valves
PROTECT TAVI - Prospective Randomized Outcome Study in TAVI Patients Undergoing Periprocedural Embolic Cerebral Protection With the Sentinel™ Device
This prospective, randomized study was designed to analyse the difference of cerebral embolization in patients undergoing transcatheter aortic valve implantation with balloon-expandable vs.
- Trial name
- PROTECT (NCT02895737)
- Testing
- TAVI: Edwards SAPIEN 3, Edwards Lifesciences, Edwards Sapien Ultra, TAVI: Edwards SAPIEN 3, Edwards Lifesciences, Edwards Sapien Ultra; Sentinel™ Cerebral Protection Systems, TAVI: CoreValve® Evolut R™, CoreValve Medtronic
- Where
- Germany
- Volunteers
- 328 people
- Sponsor
- Deutsches Herzzentrum Muenchen
Ischemic Stroke, Atheroscleroses, Cerebral
Morphology of Advanced Symptomatic Cerebral Plaques With High Embolic Potential
The study is to attain early recognition of the unstable plaques which have an imminent embolic risk in patients with intracranial atherosclerotic disease (IAD).
- Trial name
- NCT03291652
- Testing
- DSA/3DRA
- Where
- Hong Kong
- Volunteers
- 140 people
- Sponsor
- Chinese University of Hong Kong
Atrial Fibrillation, Stroke, Ischemic
Echocardiographic Predictors of Atrial Fibrillation
This prospective study aims to identify the diagnostic accuracy of echocardiographic predictors of atrial fibrillation in patients with ESUS (embolic stroke of undetermined source) or TIA (transient ischemic attack).
- Conditions
- Atrial Fibrillation, Stroke, Ischemic, Embolic Stroke of Undetermined Source, TIA, Brain
- Trial name
- EPAF-7 (NCT05044208)
- Testing
- ECG monitoring
- Where
- Austria
- Volunteers
- 200 people
- Sponsor
- Karl Landsteiner University of Health Sciences
Ischemic Attack, Transient, Stroke
Colchicine for Prevention of Vascular Inflammation in Non-cardio Embolic Stroke
This study evaluates the use of Colchicine in adults over 40 years of age who have suffered an ischaemic stroke or transient ischaemic attack NOT caused by cardiac embolism or other defined causes.
- Trial name
- CONVINCE (NCT02898610)
- Testing
- Colchicine
- Where
- 145 sites in Belgium, Canada and 12 more
- Volunteers
- 3,154 people
- Sponsor
- University College Dublin
Cardioembolic Stroke, Anticoagulant Therapy
Keeping Oral o Parental AnticoaguLation in the Acute Phase of Cardioembolic Ischemic Stroke
This is an observational, prospective, multicenter, cohort study in patients with cardioembolic stroke and previous oral or parenteral anticoagulant therapy.
- Conditions
- Cardioembolic Stroke, Anticoagulant Therapy, Stroke Recurrence, Haemorrhagic Transformation Stroke
- Trial name
- KOALA-IS (NCT05486351)
- Testing
- Observation
- Where
- 3 sites in France, Spain
- Volunteers
- 318 people
- Sponsor
- Instituto de Investigación Hospital Universitario La Paz
Ischemic Stroke, Carotid Artery Disease
Norwegian Carotid Plaque Study
BACKGROUND: In 30-40% the cause of ischemic stroke remains undetermined. Most likely, this category hides an additional number of strokes caused by artery-to-artery embolisms due to unidentified atherosclerotic disease, or caused…
- Conditions
- Ischemic Stroke, Carotid Artery Disease, Embolic Stroke
- Trial name
- NOR-PLAQ (NCT02759653)
- Where
- Norway
- Volunteers
- 16 people
- Sponsor
- Haukeland University Hospital
Embolic Stroke of Undetermined Source
Registry Study for the Observation of Patients With ESUS/Cryptogenic Stroke
Up to know, there is no clear diagnostic and therapeutic pathway for patients with embolic stroke of undetermined source (ESUS).
- Trial name
- Catch-up-ESUS (NCT03820375)
- Where
- Germany
- Volunteers
- 750 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Embolic Stroke of Undetermined Source
Cardea SOLOTM for Paroxysmal Atrial Fibrillation Diagnosis in ESUS Patients With Left Atrial Enlargement
The aim of the study is to evaluate the efficacy and safety of the Cardea SOLO Compared to 12 lead EKG for Paroxysmal Atrial Fibrillation Diagnosis in ESUS patients with Left Atrial Enlargement.
- Trial name
- NCT05431972
- Testing
- Cardea SOLO, 12 Lead EKG
- Where
- South Korea
- Volunteers
- 257 people
- Sponsor
- Asan Medical Center
Patent Foramen Ovale, Cryptogenic Stroke
Comparison of Lower vs Upper Extremity Injection Agitated Saline to Identify Patent Foramen Ovale With Echocardiography
Study Title LOwer vs upper extremity injection agitated saline for identifiCation of pATent foramen ovalE (LOCATE) Pilot study to determine safety of lower extremity injection of agitated saline for echocardiography of the heart.
- Conditions
- Patent Foramen Ovale, Cryptogenic Stroke, Embolic Infarction
- Trial name
- LOCATE (NCT07009678)
- Testing
- intravenous access in greater saphenous vein compared to upper extremity site.
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- St. John's Hospital
Ischemic Stroke, Atrial Fibrillation
Cardiac Assessment for Recurrent Stroke Risk Evaluation in Atrial Fibrillation
Background Atrial fibrillation (AF) is the most common cardiac arrhythmia, affecting up to 10% of the elderly. Ischemic stroke is the main complication of AF and cardioembolism is one of the leading causes of ischemic stroke…
- Conditions
- Ischemic Stroke, Atrial Fibrillation, Cerebrovascular Disorders, Brain Diseases
- Trial name
- CARE-AF (NCT06954610)
- Testing
- No intervention
- Where
- Switzerland
- Volunteers
- 500 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Acute Ischemic Stroke, Acute Renal Injury
Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Acute Ischemic Cerebral and Renal Events After Transcatheter Aortic Valve Implantation
The aim of this trial is to assess the safety and efficacy of conestat alfa (Ruconest®, Pharming Technologies B.V.) on renal and cerebral ischemic events in patients undergoing TAVI for severe symptomatic aortic stenosis (AS)…
- Trial name
- PAIR-TAVI (NCT05145283)
- Testing
- Conestat alfa (Ruconest®), NaCl 0.9%)
- Where
- 2 sites in Switzerland
- Volunteers
- 141 people
- Sponsor
- University Hospital, Basel, Switzerland